FUSION
Type One Raises $200M to Move Fusion From Lab to Power Plant
Type One Energy raised $200M in a Series B joined by Siemens Energy Ventures, bringing total funding past $400M — the third-largest fusion Series B in five years. The Knoxville startup is building Project Infinity at the Tennessee Valley Authority’s Bull Run site: a stellarator engineering prototype (Infinity One) and a planned 400 MWe commercial plant (Infinity Two) targeted for 2034. The pitch, in its CEO’s words: fusion’s challenge is now deployment, not discovery.
What happened
Type One raised a $200M Series B (Siemens Energy Ventures joining Bill Gates’ Breakthrough Energy Ventures); total funding now $400M+.
Funds advance Project Infinity in Tennessee — a stellarator prototype and a planned 400 MWe plant targeting 2034.
Type One aims to make Siemens a manufacturing partner, leaning on industrial firms rather than building everything itself.
Why it matters
Siemens Energy’s backing signals industrial heavyweights now see fusion as a supply-chain opportunity, not just science.
The stellarator approach trades harder engineering for steadier, continuous operation versus pulsed tokamaks.
Siting at a TVA utility gives Type One a credible path from prototype to grid connection.
For investors
Type One (private) is a top-tier commercial-fusion bet with a utility host and an industrial partner.
A named manufacturing partner de-risks the scale-up that sinks many hardware startups.
Risk: a 2034 plant is far off, valuation undisclosed, and net-energy gain is still unproven at scale.
Read more: ESG Today (October 6, 2026)
SPACE & SPACE ECONOMY
Varda Raises $251M to Make Medicines in Orbit — Routinely
Varda Space Industries raised a $251M Series D, led by Lux Capital and Natural Capital, to scale its in-space pharmaceutical manufacturing — bringing total funding to $598M. Varda flies autonomous lab capsules that use microgravity to crystallize drug ingredients in ways impossible on Earth, then returns them for landing. Having completed six launch-and-reentry missions, it now wants to make orbital manufacturing a routine step in drug development, with 12+ more missions planned by 2028.
What happened
Varda raised a $251M Series D (Lux Capital, Natural Capital, Founders Fund, Khosla); total funding $598M.
Its W-Series capsules process pharmaceutical ingredients in microgravity and return them to Earth; six missionsflown.
The capital funds higher mission cadence — 12+ more launches and reentries planned by 2028.
Why it matters
Microgravity can yield drug crystal structures impossible on Earth, potentially unlocking new, more stable formulations.
The bet is on cadence — making in-space manufacturing routine, not a one-off science demo.
Governments including the UK are building regulatory sandboxes for space-made drugs, a demand signal.
For Investors
Varda (private) leads in-space manufacturing, a rare physical-economy niche with a pharma revenue model.
A United Therapeutics partnership and the goal of the first space-made medicine give it commercial anchors.
Risk: capital-intensive and launch-dependent — one capsule burned up on reentry in May, underscoring execution risk.
Read more: SpaceNews (October 1, 2026)
ROBOTICS & AUTOMATION
Mecka Raises $60M to Be the Training-Data Layer for Robots
Mecka AI raised a $60M Series B led by Sequoia Capital, with Nvidia, Microsoft’s M12, Qualcomm, and Samsung — reportedly at around a $500M valuation. The Toronto and New York startup pays people to perform everyday tasks while wearing body sensors, turning human motion into training data for humanoid and embodied-AI robots. The thesis: the bottleneck in robotics isn’t hardware, it’s data — and recording people is the fastest way to teach machines to move.
What happened
Mecka raised a $60M Series B (Sequoia-led, with Nvidia, M12, Qualcomm, Samsung); total funding past $120M.
It builds EgoVerse, a human-motion dataset, by paying people to record tasks with sensors and phones.
Mecka claims a $100M+ run-rate (June), projecting $300M by year-end, as it expands into robot deployment.
Why it matters
Training data is the binding constraint for embodied AI — Mecka aims to be “Scale AI for robots.”
Capturing human motion, rather than robot trials, may be the fastest route to generalizable skills.
Strategic backers (Nvidia, Samsung, Qualcomm) signal the robotics-data layer is now contested ground.
For Investors
Mecka (private) is a picks-and-shovels bet on the humanoid boom, selling to many robot makers at once.
Rare for the sector, it reports real revenue rather than pure burn.
Risk: the run-rate claims are unverified, the founders are new to robotics, and data-layer moats are unproven.
Read more: BetaKit (October 7, 2026)
NEUROTECHNOLOGY & BCI
Paradromics Shows Four Years of Stable Brain Recording
Paradromics said its brain-computer interface achieved more than four years of stable neural recording and decoding in preclinical testing — a durability milestone the field has long chased. Its Connexus BCI reads activity from individual neurons at over 200 bits per second, roughly 20x faster than existing interfaces. Durability, the company argues, is a safety issue: an implant meant to last decades has to prove it won’t degrade. The result lands as Paradromics moves into its first-in-human study.
What happened
Paradromics reported 4+ years of stable neural recording in long-term preclinical (sheep) studies, with signal quality holding.
Its Connexus BCI captures single-neuron activity at 200+ bits/sec — about 20x faster than existing BCIs.
The milestone comes as Paradromics advances its Connect-One first-in-human study.
Why it matters
Long-term durability is the hurdle between a demo and an implant people can rely on for years.
Framing durability as a safety issue aligns with what regulators and surgeons need to see.
It extends the BCI momentum from recent raises (Precision Neuroscience’s $250M) into a hard clinical proof point.
For investors
Paradromics (private) is a leading high-bandwidth implanted-BCI player now entering the clinic.
Durability data de-risks the long road to a permanent, decade-scale implant.
Risk: results are preclinical animal data; human trials are only beginning, and BCI timelines remain long.
Read more: Business Wire (October 8, 2026)
PARTNER SPOTLIGHT
EYWA by R.Evolution × Longevity Investors
EYWA by R.Evolution is a global regenerative real estate brand redefining what it means to live well. In partnership with Longevity Investors, EYWA creates living ecosystems where architecture, technology, and ancient wisdom converge to elevate human health, measurable wellbeing, and long-term prosperity — translating longevity science directly into the built environment. This is where capital aligns with healthspan infrastructure, and a new category of conscious living begins.
Architecture as a carrier of health — buildings designed from the ground up around the biology of the people inside them
Technology as an amplifier of ancient wisdom — biometric data and natural systems integrated at the design level
Wellbeing as a measurable asset — longevity science embedded in every structural and environmental decision
Community as a protective layer — a curated global ecosystem of health-conscious individuals
IP as scalable value — a multi-platform ecosystem for designing human life, built to grow with the science
What signals should be on our radar?
If you’d like to be featured, spotlight a deal, or explore a partnership, just reply to this email and we’ll take it from there.
We’re all ears on how to make Future Investments News truly indispensable for you -tell us what would make this your go-to read on frontier tech and the next decade of investment. If this issue delivered value, please forward it to a colleague or LP.
Disclaimer
Prepared by Future Investments News for general information only; not investment, legal, or tax advice. No offer or solicitation to buy or sell any security or financial instrument. Past trends and transactions are not reliable indicators of future results. Readers should conduct their own due diligence and consult qualified advisers before making decisions.
Stay ahead,
Future Investments News team.
Future Investments News — Signals shaping the next decade of investment.